Ontology highlight
ABSTRACT:
SUBMITTER: Dohner H
PROVIDER: S-EPMC4148765 | biostudies-literature | 2014 Aug
REPOSITORIES: biostudies-literature
Döhner Hartmut H Lübbert Michael M Fiedler Walter W Fouillard Loic L Haaland Alf A Brandwein Joseph M JM Lepretre Stephane S Reman Oumedaly O Turlure Pascal P Ottmann Oliver G OG Müller-Tidow Carsten C Krämer Alwin A Raffoux Emmanuel E Döhner Konstanze K Schlenk Richard F RF Voss Florian F Taube Tillmann T Fritsch Holger H Maertens Johan J
Blood 20140708 9
Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of polo-like kinases. Eighty-seven patients (median age 75 years) received LDAC 20 mg twice daily subcutaneously days 1-10 or LDAC + volasertib 350 mg IV days 1 + 15 every 4 weeks. Response rate (com ...[more]